NCT05232708View on ClinicalTrials.gov

A Clinical Trial Looking at the Comparability of 2 Different Forms of Semaglutide

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

January 19, 2022

Primary Completion Date

August 30, 2022

Study Completion Date

August 30, 2022

Conditions
Healthy Volunteers (Diabetes Mellitus, Type 2)
Interventions
DRUG

Semaglutide B, 1.34 mg/mL

Subjects will receive single dose of 0.5 mg Semaglutide B, 1.34 mg/mL subcutaneously.

DRUG

Semaglutide D, 1.0 mg/mL

Subjects will receive single dose of 0.5 mg Semaglutide D, 1.0 mg/mL subcutaneously.

DRUG

Semaglutide D, 1.0 mg/mL

Subjects will receive single dose of 0.5 mg Semaglutide D, 1.0 mg/mL subcutaneously.

DRUG

Semaglutide B, 1.34 mg/mL

Subjects will receive single dose of 0.5 mg Semaglutide B, 1.34 mg/mL subcutaneously.

Trial Locations (1)

HA1 3UJ

Parexel CPRU, Level 7, Harrow

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY